Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 15/20 | 0.38 |
| ▸ | NMT2 | O60551 | 14/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21335165 | 0.93 | CPB2 (0.34) | NMT1NMT2CPB2KDM1A | |
| SCHEMBL17992337 | 0.92 | NMT1 (0.38) | NMT1NMT2CPB2 | |
| SCHEMBL22106106 | 0.91 | CPB2 (0.34) | NMT1NMT2CPB2KDM1A | |
| SCHEMBL22106107 | 0.91 | CPB2 (0.34) | NMT1NMT2CPB2KDM1A | |
| SCHEMBL24564906 | 0.86 | NMT1 (0.39) | NMT1NMT2CPB2 | |
| SCHEMBL21335196 | 0.86 | MMP1 (0.43) | — | |
| SCHEMBL17992368 | 0.85 | CPB2 (0.34) | NMT1NMT2CPB2KDM1A | |
| SCHEMBL21335154 | 0.85 | CPB2 (0.34) | NMT1NMT2CPB2KDM1A | |
| SCHEMBL17992370 | 0.85 | CPB2 (0.34) | NMT1NMT2CPB2KDM1A | |
| SCHEMBL21335138 | 0.85 | CPB2 (0.34) | NMT1NMT2CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200188476-A1 | ANTI-MICROBIAL AGENT-POLYMER CONJUGATES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2020-06-18 | — | — | US | disclosed |
| US-10407467-B2 | Polymyxin derivatives and their use in combination therapy together with different antibiotics | NEW PHARMA LICENCE HOLDINGS LIMITED (MT) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200188476-A1 | ANTI-MICROBIAL AGENT-POLYMER CONJUGATES AND METHODS OF USE THEREOF | DDOST, MGAM, MSN | NMT1 1151/4885NMT2 1170/4885CPB2 1548/4885 |
| US-10407467-B2 | Polymyxin derivatives and their use in combination therapy together with different antibiotics | MRPS18A, MRPL21, RRP1B | NMT1 2823/4885NMT2 3309/4885CPB2 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.